Overview Fundamentals API Earnings EOD API Sample Code Pricing

Biofrontera AG (BFFTF PINK) stock market data APIs

$22.68 0(0%) as of July 5, 2024
Price chart is built with Anychart

Biofrontera AG, a biopharmaceutical company, engages in the research, development, and distribution of dermatological products in Germany, Spain, the United Kingdom, rest of Europe, the United States, and internationally. The company offers Ameluz and BF-RhodoLED lamp for the treatment of mild and moderate actinic keratoses on the face and scalp, field cancerization, and fatal squamous cell carcinoma. It also provides RhodoLED XL lamp for the treatment of multiple interspersed lesions; and Belixos, a cosmetic product for irritated and sensitive skin. The company has a license and supply agreement with Maruho Co., Ltd. Biofrontera AG was founded in 1997 and is headquartered in Leverkusen, Germany.

Biofrontera AG Financial Data Overview

42 113 K
6 077 K
30 163 K
Our easy-to-use no-coding solutions help you get the data effortlessly:

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'BFFTF',
Type: 'Common Stock',
Name: 'Biofrontera AG',
Exchange: 'PINK',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
OpenFigi: 'BBG00JGMJFW3',
CIK: '1712641',
EmployerIdNumber: NULL,
FiscalYearEnd: 'December',
InternationalDomestic: NULL,
Sector: 'Healthcare',
Industry: 'Drug Manufacturers - Specialty & Generic',
HomeCategory: NULL,
IsDelisted: false,

Biofrontera AG Fundamental Data is available in our Financial Data APIs

  • Net Revenue 30 163 K
  • EBITDA 4 241 K
  • Earnings Per Share -7.8
  • Income Statements
  • Balance Sheets
  • Cash flows
Get sample
of Fundamental API Data

Get Biofrontera AG Earnings via APIs

  • Latest Release 2023-12-31
  • EPS/Forecast NaN

Get Biofrontera AG End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends
Do you have any questions?